Difference between revisions of "Rituximab (Rituxan)"
m (updated diseases) |
|||
| Line 14: | Line 14: | ||
*[http://chemocare.com/bio/rituximab.asp Rituximab (Rituxan) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/rituximab.asp Rituximab (Rituxan) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/rituximab.asp Rituximab (Rituxan) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/rituximab.asp Rituximab (Rituxan) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *October 19th, 2012: 90 minute infusion starting with cycle 2 approved | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 21:16, 19 October 2012
General information
Class/mechanism: Anti-CD20 antibody, chimeric murine/human monoclonal IgG1 kappa, which binds to CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), which is expressed on B-cells. The Fc domain recruits immune effector functions to mediate B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Lymphocyte predominant Hodgkin Lymphoma
- Non-Hodgkin lymphoma
Patient drug information
- Rituximab (Rituxan) patient drug information (Chemocare)[4]
- Rituximab (Rituxan) patient drug information (UpToDate)[5]
History of changes in FDA indication
- October 19th, 2012: 90 minute infusion starting with cycle 2 approved